The weighted-average grant-date fair values of stock options granted during the nine-month periods ended September 29, 2019 and September 30, 2018 were $18.58 and $21.70, respectively.
In the determination of the lease term, the Company considers the existence of extension or termination options and the probability of those options being exercised.
If that callable debt security is subsequently called, the entity records a loss equal to the unamortized premium.
 (1) In addition to the vested options, the Company expects a portion of the unvested options to vest at some point in the future.
Options expected to vest are calculated by applying an estimated forfeiture rate to the unvested options.
As a practical expedient, the Company accounts for the non-lease components together with the lease components as a single lease component for all of its leases.
The total intrinsic values of stock options exercised for the three-month periods ended September 29, 2019 and September 30, 2018 were $5,746,000 and $17,985,000, respectively.
Equity awards to purchase 6,078,000 and 5,695,000 shares of common stock, on a weighted-average basis, were outstanding during the three-month and nine-month periods ended September 29, 2019, respectively, and 2,796,000 and 2,353,000 for the same periods in 2018, but were not included in the calculation of dilutive net income per share because they were anti-dilutive.
Certain leases contain leasehold improvement incentives, retirement obligations, escalating clauses, rent holidays, and variable payments tied to a consumer price index.
The Company records the estimated cost of fulfilling product warranties at the time of sale based upon historical costs to fulfill claims.
The amendments in this ASU require that credit losses on available-for-sale debt securities be presented as an allowance rather than as a write-down and an entity will be able to record reversals of credit losses in current period net income.
Equity awards to purchase 6,078,000 and 5,695,000 shares of common stock, on a weighted-average basis, were outstanding during the three-month and nine-month periods ended September 29, 2019, respectively, and 2,796,000 and 2,353,000 for the same periods in 2018, but were not included in the calculation of dilutive net income per share because they were anti-dilutive.Cognex machine vision is primarily used to automate manufacturing and distribution processes in a variety of industries where the technology is widely recognized as an important component of automated production and quality assurance.
Virtually every manufacturer can achieve better quality and manufacturing efficiency by using machine vision, and therefore, Cognex products are used by a broad base of customers across a variety of industries, including consumer electronics, automotive, consumer products, food and beverage, pharmaceuticals, and medical devices.
In addition, the Company has no long-term debt and does not anticipate needing debt financing in the near future.
In addition, the effective tax rate included a decrease in tax expense of $1,327,000 for the three-month period and $1,330,000 for the nine-month period in 2019, respectively, consisting primarily of the expiration of the statutes of limitations for certain reserves for income tax uncertainties.
Certain statements made in this report, as well as oral statements made by the Company from time to time, constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company recorded other income of $456,000 and $1,239,000 for the three-month and nine-month periods in 2019, respectively, compared to other expense of $129,000 and $98,000 for the same periods in 2018.